Centessa Pharmaceuticals plc - ADR Stock

$13.20

7.67% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US1523091007

Symbol

CNTA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Centessa Pharmaceuticals plc - ADR Stock price

$13.20

-8.55 39.31% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.94 7.67%

ISIN

US1523091007

Symbol

CNTA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$1.76b
Enterprise Value	$1.60b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	106.00
P/S ratio (TTM) P/S ratio	117.06
P/B ratio (TTM) P/B ratio	4.56
Revenue growth (TTM) Revenue growth	117.83%
Revenue (TTM) Revenue	$15.06m
EBIT (operating result TTM) EBIT	$-195.69m
Free Cash Flow (TTM) Free Cash Flow	$-162.35m
Cash position	$284.51m
EPS (TTM) EPS	$-1.80
P/E forward	negative
P/S forward	130.59
EV/Sales forward	118.25
Short interest	4.70%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Centessa Pharmaceuticals plc - ADR Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

10x Buy

100%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Centessa Pharmaceuticals plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	15 15	118% 118% 100%
- Direct Costs	0.92 0.92	4% 4% 6%
Gross Profit	14 14	138% 138% 94%
- Selling and Administrative Expenses	48 48	3% 3% 318%
- Research and Development Expense	161 161	41% 41% 1,069%
EBITDA	-195 -195	23% 23% -1,293%
- Depreciation and Amortization	0.92 0.92	4% 4% 6%
EBIT (Operating Income) EBIT	-196 -196	23% 23% -1,299%
Net Profit	-223 -223	61% 61% -1,483%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Centessa Pharmaceuticals plc - ADR Stock News

Neutral

GlobeNewsWire

●

one day ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Neutral

GlobeNewsWire

●

7 days ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

BOSTON and LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for the first quarter ended March 31, 2025.

Neutral

GlobeNewsWire

●

about 2 months ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2024.

More Centessa Pharmaceuticals plc - ADR News

Company Profile

Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company was founded on October 26, 2020 and is headquartered in Cambridge, the United Kingdom.

Head office	United Kingdom
CEO	Saurabh Saha
Employees	77
Founded	2013
Website	centessa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now